Systemic chemotherapy is modulated by platelet-activating factor-receptor agonists

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Sahu, Ravi P ^a   Ferracini, Matheus ^a   Travers, Jeffrey B ^b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMOYL THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; ETOPOSIDE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG; 1-O-HEXADECYL-2-N-METHYLCARBAMOL -SN-GLYCEROL-3-PHOSPHOCHOLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MELANOMA; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC THERAPY; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR XENOGRAFT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; MELANOMA; METASTASIS; SIGNAL TRANSDUCTION;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ETOPOSIDE; FEMALE; IMMUNOSUPPRESSION; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84928243519     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/820543     Document Type: Article

References (35)

1. A. J. Miller and M. C. Mihm Jr., "Melanoma," The New England Journal of Medicine, vol. 355, no. 1, pp. 51-65, 2006.
2. N. Howlader, A. M. Noone, M. Krapcho et al., SEER Cancer Statistics Review, 1975-2010, National Cancer Institute, Bethesda,Md, USA, 2012, http://seer. cancer. gov/csr/1975 2010/, http://seer. cancer. gov/statfacts/html/melan. html.
3. J. Treisman and N. Garlie, "Systemic therapy for cutaneous melanoma," Clinics in Plastic Surgery, vol. 37, no. 1, pp. 127-146, 2010.
4. M. B. Lens and T. G. Eisen, "Systemic chemotherapy in the treatment ofmalignantmelanoma," ExpertOpinion on Pharmacotherapy, vol. 4, no. 12, pp. 2205-2211, 2003.
5. W. J. Hwu, "New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide," Oncology, vol. 12, supplement 13, pp. 25-28, 2000.
6. C. K. Kissel, D. Schadendorf, and H. Röckmann, "The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific," Melanoma Research, vol. 16, no. 6, pp. 527-535, 2006.
7. H. Helmbach, M. A. Kern, E. Rossmann et al., "Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency," Journal of Investigative Dermatology, vol. 118, no. 6, pp. 923-932, 2002.
8. A. R. Bowen, A. N. Hanks, S. M. Allen, A. Alexander, M. J. Diedrich, and D. Grossman, "Apoptosis regulators and responses in human melanocytic and keratinocytic cells," Journal of Investigative Dermatology, vol. 120, no. 1, pp. 48-55, 2003.
9. C. Grottke, K. Mantwill, M. Dietel, D. Schadendorf, and H. Lage, "Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs," International Journal ofCancer, vol. 88,no. 4, pp. 535-546, 2000.
10. K. A. Conklin, "Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness," Integrative Cancer Therapies, vol. 3, no. 4, pp. 294-300, 2004.
11. S. Arora, A. Bhardwaj, S. Singh et al., "An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor B-and hypoxia-inducible factor 1-mediated up-regulation of CXCR4,"The Journal of Biological Chemistry, vol. 288, no. 29, pp. 21197-21207, 2013.
12. K. Qu, T. Lin, Z. Wang et al., "Reactive oxygen species generation is essential for cisplatininduced accelerated senescence in hepatocellular carcinoma," Frontiers of Medicine in China, vol. 8, no. 2, pp. 227-235, 2014.
13. J. P. Walterscheid, S. E. Ullrich, and D. X. Nghiem, "Plateletactivating factor, a molecular sensor for cellular damage, activates systemic immune suppression," Journal of Experimental Medicine, vol. 195, no. 2, pp. 171-179, 2002.
14. J. B. Travers, D. Berry, Y. Yao, Q. Yi, R. L. Konger, and J. B. Travers, "Ultraviolet B radiation of human skin generates platelet-activating factor receptor agonists," Photochemistry and Photobiology, vol. 86, no. 4, pp. 949-954, 2010.
15. R. L. Konger, G. K. Marathe, Y. Yao, Q. Zhang, and J. B. Travers, "Oxidized glycerophosphocholines as biologically active mediators for ultraviolet radiation-mediated effects," Prostaglandins and Other Lipid Mediators, vol. 87, no. 1-4, pp. 1-8, 2008.
16. Y. Yao, J. E. Wolverton, Q. Zhang et al., "Ultraviolet B radiation generated platelet-activating factor receptor agonist formation involves EGF-R-mediated reactive oxygen species," The Journal of Immunology, vol. 182, no. 5, pp. 2842-2848, 2009.
17. R. P. Sahu, I. Petrache,M. J. vanDemark et al., "Cigarette smoke exposure inhibits contact hypersensitivity via the generation of platelet-activating factor agonists," The Journal of Immunology, vol. 190, no. 5, pp. 2447-2454, 2013.
18. D. M. Stafforini, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott, "Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes," Critical Reviews in Clinical Laboratory Sciences, vol. 40, no. 6, pp. 643-672, 2003.
19. N. B. Countryman, Y. Pei, Q. Yi,D. F. Spandau, and J. B. Travers, "Evidence for involvement of the epidermal platelet activating factor receptor in ultraviolet-B-radiation induced interleukin-8 production," Journal of Investigative Dermatology, vol. 115, no. 2, pp. 267-272, 2000.
20. J. B. Travers, J. C. Huff, M. Rola-Pleszczynski, E. W. Gelfand, J. G. Morelli, and R. C. Murphy, "Identification of functional plateletactivating factor receptors on human keratinocytes," Journal of Investigative Dermatology, vol. 105, no. 6, pp. 816-823, 1995.
21. R. P. Sahu, Y. Yao, R. L. Konger, and J. B. Travers, "Plateletactivating factor does not mediate uvb-induced local immune suppression," Photochemistry and Photobiology, vol. 88, no. 2, pp. 490-493, 2012.
22. S. E. Ullrich, "Mechanisms underlying UV-induced immune suppression," Mutation Research, vol. 571, no. 1-2, pp. 185-205, 2005.
23. Q. Zhang, Y. Yao, R. L. Konger et al., "UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system," Journal of Investigative Dermatology, vol. 128, no. 7, pp. 1780-1787, 2008.
24. J. B. Travers, H. J. Edenberg, Q. Zhang et al., "Augmentation of UVB radiation-mediated early gene expression by the epidermal platelet-activating factor receptor," Journal of Investigative Dermatology, vol. 128, no. 2, pp. 455-460, 2008.
25. R. P. Sahu, M. J. Turner, S. C. Dasilva et al., "The environmental stressor ultraviolet B radiation inhibits murine antitumor immunity through its ability to generate platelet-activating factor agonists," Carcinogenesis, vol. 33, no. 7, pp. 1360-1367, 2012.
26. P. C. Hackler, S. Reuss, R. L. Konger, J. B. Travers, and R. P. Sahu, "Systemic platelet-activating factor receptor activation augments experimental lung tumor growth and metastasis," Cancer Growth and Metastasis, vol. 7, pp. 27-32, 2014.
27. V. O. Melnikova, G. J. Villares, and M. Bar-Eli, "Emerging roles of PAR-1 and PAFR in melanoma metastasis," Cancer Microenvironment, vol. 1, no. 1, pp. 103-111, 2008.
28. S. I. deOliveira, L. N. S. Andrade, A. C. Onuchic et al., "Plateletactivating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy," BMC Cancer, vol. 10, article 200, 2010.
29. R. P. Sahu, J. A. Ocana, K. A. Harrison et al., "Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor," Cancer Research, vol. 74, no. 23, pp. 7069-7078, 2014.
30. M. H. Giles and B. J. Coventry, "Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit," Cancer Management and Research, vol. 5, no. 1, pp. 243-249, 2013.
31. S. Cai, T. R. Bagby, and M. L. Forrest, "Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies," Therapeutic Delivery, vol. 2, no. 11, pp. 1467-1484, 2011.
32. S. Taymouri and J. Varshosaz, "The recent progresses on the improved therapy ofmelanoma by novel drug delivery systems," Current Drug Targets, vol. 15, no. 9, pp. 829-842, 2014.
33. M. Ferracini, R. P. Sahu, K. A. Harrison et al., "Topical photodynamic therapy induces systemic immunosuppression via generation of platelet-activating factor receptor ligands," Journal of Investigative Dermatology, vol. 135, no. 1, pp. 321-323, 2014.
34. K. H. Seo, H.-M. Ko, H.-A. Kimet al., "Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-B activation," Cancer Research, vol. 66, no. 9, pp. 4681-4686, 2006.
35. A. C. Onuchic, C. M. L. MacHado, R. F. Saito, F. J. Rios, S. Jancar, and R. Chammas, "Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in melanoma,"Mediators of Inflammation, vol. 2012, Article ID175408, 6 pages, 2012.